Volume 8.11 | Mar 24

Cord Blood News 8.11 March 24, 2016
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  CBN on Twitter
Genome-Wide RNAi Screen Identifies Cohesin Genes as Modifiers of Renewal and Differentiation in Human HSCs
To gain insights into the regulatory mechanisms of hematopoietic stem cells (HSCs), investigators employed a genome-wide RNAi screen in human cord-blood derived cells and identified candidate genes whose knockdown maintained the HSC phenotype during culture. [Cell Rep] Full Article | Graphical Abstract
Learn more about new StemSpan™ Erythroid Expansion Medium. Combine with Erythroid Expansion Supplement to generate 1000s of erythroid cells per input human CD34+ cell in ACF conditions.
PUBLICATIONS (Ranked by impact factor of the journal)
Adipogenic Placenta-Derived Mesenchymal Stem Cells Are Not Lineage Restricted by Withdrawing Extrinsic Factors: Developing a Novel Visual Angle in Stem Cell Biology
Researchers showed that after withdrawing extrinsic factors, adipogenic placental-derived mesenchymal stem cells reverted to a primitive cell population and retained stem cell characteristics. The mitochondrial network during differentiation and dedifferentiation may serve as a marker of absent or acquired pluripotency in various stem cell models. [Cell Death Dis] Full Article

Role of VEGF-A in Angiogenesis Promoted by Umbilical Cord-Derived Mesenchymal Stromal/Stem Cells: In Vitro Study
The authors describe pro-angiogenic properties of mesenchymal stromal/stem cells derived from human umbilical cord as manifested in vitro. [Stem Cell Res Ther] Abstract

Enhanced Expression of Hepatocyte-Specific microRNAs in Valproic Acid Mediated Hepatic Trans-Differentiation of Human Umbilical Cord Derived Mesenchymal Stem Cells
Investigators analyzed the expression pattern of microRNAs during hepatic trans-differentiation. The protocol employed the use of histone deacetylase inhibitor, valproic acid to induce hepatic trans-differentiation of human umbilical cord Wharton’s jelly derived mesenchymal stem cells. [Exp Cell Res] Abstract

Assessment of Glial Scar, Tissue Sparing, Behavioral Recovery and Axonal Regeneration following Acute Transplantation of Genetically Modified Human Umbilical Cord Blood Cells in a Rat Model of Spinal Cord Contusion
Researchers investigated the potential for protective effects of human umbilical cord blood mononuclear cells (UCB-MCs) genetically modified with the VEGF and GNDF genes on contusion spinal cord injury (SCI) in rats. They showed that a gene delivery using UCB-MCs-expressing VEGF and GNDF genes improved both structural and functional parameters after SCI. [PLoS One] Full Article

Amelioration of Ischemic Brain Injury in Rats with Human Umbilical Cord Blood Stem Cells: Mechanisms of Action
Scientists have tested a human umbilical cord blood-derived stem cell line that has shown both a significant reduction in stroke infarct volume as well as improved functional recovery following stroke in the rat. In the present study, they addressed the mechanism of action and compared therapeutic efficacy of high vs. low passage non-hematopoietic umbilical cord blood stem cells. [Cell Transplant] Abstract

Early Human Herpes Virus Type 6 Reactivation in Umbilical Cord Blood Allogeneic Stem Cell Transplantation
The authors investigated human herpes virus type 6 reactivation within 60 days of transplantation in stem cell transplants utilizing single umbilical cord blood, double umbilical cord blood, or umbilical cord blood plus haploidentical stem cells. [Leuk Lymphoma] Abstract

Human Umbilical Cord Blood Mononuclear Cells and Chorionic Plate-Derived Mesenchymal Stem Cells Promote Axon Survival in a Rat Model of Optic Nerve Crush Injury
A rat model of optic nerve crush (ONC) injury was established in order to examine the effects of transplanting human chorionic plate-derived mesenchymal stem cells isolated from the placenta, as well as human umbilical cord blood mononuclear cells on compressed rat optic nerves. [Int J Mol Med] Abstract

Get More of the Cells You Need with StemSpan™ CD34+ Cell Expansion Supplement and StemSpan™ SFEM
Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma
Recent studies highlight comparable results with haploidentical SCT and cord blood SCT, thus providing alternate donor sources. Disease relapse and late effects continue to be major problems. Optimization of SCT techniques, post-transplant monitoring of minimal residual disease, and post-transplant maintenance, or pre-emptive therapy are emerging strategies to reduce the risk of relapse. [Curr Hematol Malig Rep] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.
Kite Pharma Announces Clinical Collaboration to Evaluate Two Novel Immunotherapies for Patients with Non-Hodgkin Lymphoma
Kite Pharma, Inc. announced that it has entered into a clinical trial collaboration with Genentech, a member of the Roche Group, to evaluate the safety and efficacy of KTE-C19, in combination with atezolizumab, in patients with refractory, aggressive non-Hodgkin lymphoma. [Kite Pharma, Inc.] Press Release

Blavatnik Biomedical Accelerator at Harvard University Announces License and Collaboration Agreement with Merck to Develop Novel Cancer Therapeutics
Harvard University has entered into an exclusive license and research collaboration agreement with Merck to further the development of small-molecule therapeutics for leukemia and other cancers. The novel compounds, developed in the laboratory of Harvard scientist Matthew Shair, Ph.D., offer an innovative approach to cancer treatment, targeting enzymes that regulate transcription. [Harvard Office of Technology Development] Press Release

From our sponsor:
Webinar: Brent Reynolds on the identification and characterization of neural stem cells.
Watch now.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW World Cord Blood Europe
May 18-19, 2016
London, United Kingdom

Visit our events page to see a complete list of events in the cord blood community.
NEW Postdoctoral Research Associate – Pediatric Acute Lymphoblastic Leukemia (University of Pittsburgh)

Postdoctoral Research Associate – Blood Stem cell Microenvironment (University of Illinois)

Associate Scientist – Hematopoietic Stem Cell Biology (Editas Medicine)

Research Associate – Hematopoietic Stem Cell Biology (Editas Medicine)

Postdoctoral Fellow – Hematology/Oncology (Boston Children’s Hospital)

Research Fellow – Erythropoiesis (New York Blood Center)

Postdoctoral Fellow – Stem Cell Biology and Regenerative Medicine (Cleveland Clinic)

Translational Research Scientist – Hematology/Oncology (University of Chicago)

Postdoctoral Associate – Epigenetic Regulation of Normal and Leukemic Stem Cells (Sanford Burnham Prebys Medical Discovery Institute)

Postdoctoral Positions – Immunology, Cancer, and Stem Cells (University of Connecticut)

PhD Position – Stem Cells and Transplantation (University of Geneva)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us